Aleksandra M. Michalowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aleksandra M. Michalowski has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Jing Huang
National Cancer Institute 1 Cancer and Stem Cell Epigenetics, Laboratory of Cancer Biology and Genetics, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
31 shared publications - Howard Yang
Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
30 shared publications - Andy D. Tran
Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
29 shared publications - Gamze Ayaz
National Cancer Institute 1 Cancer and Stem Cell Epigenetics, Laboratory of Cancer Biology and Genetics, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
29 shared publications - Hualong Yan
National Cancer Institute 1 Cancer and Stem Cell Epigenetics, Laboratory of Cancer Biology and Genetics, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
29 shared publications - Kent W. Hunter
Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
29 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
The oxidoreductase CLIC4 controls UCP-2 expression to support mitochondrial function in macrophages
The Chloride Intracellular Channel-4 (CLIC4) is one of six highly conserved proteins in the CLIC family that share high structural homology with glutathione-S-transferase (GST)-omega in the GST superfamily. While CLIC4 is a multifunctional protein that resides in multiple cellular compartments, the discovery of its enzymatic glutaredoxin-like activity in vitro suggested that it could be one of the essential oxidoreductases in cells. Here we show that macrophages lacking Clic4 display a variety of phenotypes including a failure to sustain cytokine production and reduced phagocytosis suggesting a role for Clic4 in metabolic fitness. Null cells have elevated levels of ROS as well as defective cellular energetics and reduced ATP levels. Mechanistically we find that stimulated Clic4 null cells have exacerbated expression of the negative regulator of mitochondrial ROS, UCP2. Accordingly, inhibition of UCP2 restores macrophage energetics and phagocytic activity in vitro and in vivo. We propose a model where Clic4 restrains UCP2 expression by dampening cellular ROS levels thereby preserving the mitochondrial function necessary for highly energetic activities including sustained cytokine production and phagocytosis. Our findings raise the possibility of targeting CLIC4 to induce macrophage hypophagia as a mechanism of innate immune exhaustion to improve some essential therapeutic outcomes for inflammatory diseases and related cancers.
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe oxidoreductase CLIC4 controls UCP-2 expression to support mitochondrial function in macrophages
The Chloride Intracellular Channel-4 (CLIC4) is one of six highly conserved proteins in the CLIC family that share high structural homology with glutathione-S-transferase (GST)-omega in the GST superfamily. While CLIC4 is a multifunctional protein that resides in multiple cellular compartments, the discovery of its enzymatic glutaredoxin-like activity in vitro suggested that it could be one of the essential oxidoreductases in cells. Here we show that macrophages lacking Clic4 display a variety of phenotypes including a failure to sustain cytokine production and reduced phagocytosis suggesting a role for Clic4 in metabolic fitness. Null cells have elevated levels of ROS as well as defective cellular energetics and reduced ATP levels. Mechanistically we find that stimulated Clic4 null cells have exacerbated expression of the negative regulator of mitochondrial ROS, UCP2. Accordingly, inhibition of UCP2 restores macrophage energetics and phagocytic activity in vitro and in vivo. We propose a model where Clic4 restrains UCP2 expression by dampening cellular ROS levels thereby preserving the mitochondrial function necessary for highly energetic activities including sustained cytokine production and phagocytosis. Our findings raise the possibility of targeting CLIC4 to induce macrophage hypophagia as a mechanism of innate immune exhaustion to improve some essential therapeutic outcomes for inflammatory diseases and related cancers.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1-9 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This file contains supplementary figure 1-9.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-9 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This file contains supplementary figure 1-9.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 3.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 3.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 2.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 2.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 1.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 1.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4. from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 4.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4. from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 4.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
Understanding functional interactions between cancer mutations is an attractive strategy for discovering unappreciated cancer pathways and developing new combination therapies to improve personalized treatment. However, distinguishing driver gene pairs from passenger pairs remains challenging. Here, we designed an integrated omics approach to identify driver gene pairs by leveraging genetic interaction analyses of top mutated breast cancer genes and the proteomics interactome data of their encoded proteins. This approach identified that PIK3CA oncogenic gain‐of-function (GOF) and CBFB loss‐of‐function (LOF) mutations cooperate to promote breast tumor progression in both mice and humans. The transcription factor CBFB localized to mitochondria and moonlighted in translating the mitochondrial genome. Mechanistically, CBFB enhanced the binding of mitochondrial mRNAs to TUFM, a mitochondrial translation elongation factor. Independent of mutant PI3K, mitochondrial translation defects caused by CBFB LOF led to multiple metabolic reprogramming events, including defective oxidative phosphorylation, the Warburg effect, and autophagy/mitophagy addiction. Furthermore, autophagy and PI3K inhibitors synergistically killed breast cancer cells and impaired the growth of breast tumors, including patient‐derived xenografts carrying CBFB LOF and PIK3CA GOF mutations. Thus, our study offers mechanistic insights into the functional interaction between mutant PI3K and mitochondrial translation dysregulation in breast cancer progression and provides a strong preclinical rationale for combining autophagy and PI3K inhibitors in precision medicine for breast cancer.Significance:CBFB-regulated mitochondrial translation is a regulatory step in breast cancer metabolism and synergizes with mutant PI3K in breast cancer progression.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
Understanding functional interactions between cancer mutations is an attractive strategy for discovering unappreciated cancer pathways and developing new combination therapies to improve personalized treatment. However, distinguishing driver gene pairs from passenger pairs remains challenging. Here, we designed an integrated omics approach to identify driver gene pairs by leveraging genetic interaction analyses of top mutated breast cancer genes and the proteomics interactome data of their encoded proteins. This approach identified that PIK3CA oncogenic gain‐of-function (GOF) and CBFB loss‐of‐function (LOF) mutations cooperate to promote breast tumor progression in both mice and humans. The transcription factor CBFB localized to mitochondria and moonlighted in translating the mitochondrial genome. Mechanistically, CBFB enhanced the binding of mitochondrial mRNAs to TUFM, a mitochondrial translation elongation factor. Independent of mutant PI3K, mitochondrial translation defects caused by CBFB LOF led to multiple metabolic reprogramming events, including defective oxidative phosphorylation, the Warburg effect, and autophagy/mitophagy addiction. Furthermore, autophagy and PI3K inhibitors synergistically killed breast cancer cells and impaired the growth of breast tumors, including patient‐derived xenografts carrying CBFB LOF and PIK3CA GOF mutations. Thus, our study offers mechanistic insights into the functional interaction between mutant PI3K and mitochondrial translation dysregulation in breast cancer progression and provides a strong preclinical rationale for combining autophagy and PI3K inhibitors in precision medicine for breast cancer.Significance:CBFB-regulated mitochondrial translation is a regulatory step in breast cancer metabolism and synergizes with mutant PI3K in breast cancer progression.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S1-9 from Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer
This file contains supplementary figure 1-9.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-9 from Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer
This file contains supplementary figure 1-9.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S1-9 from Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer
This file contains supplementary figure 1-9.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-9 from Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer
This file contains supplementary figure 1-9.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer
This is supplementary Table 2.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer
This is supplementary Table 2.